14-04-2025 20:01 via medpagetoday.com

Tolebrutinib Benefits Non-Relapsing Secondary Progressive Multiple Sclerosis

(MedPage Today) -- SAN DIEGO--Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.
The Bruton's tyrosine kinase (BTK...

ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up

Is Trump Getting Guideline-Recommended Care for Cardiac Risk?

RFK Jr.'s Plans on Autism Include Studying Potential Environmental Risks

U.S. Measles Cases Likely Underreported, CDC Says

Honing Indications for Endocrine Therapy in ER-Low Early Breast Cancer

Detectable ctDNA Before Adjuvant Therapy for Melanoma May Predict Recurrence

With the Threat of ICE Raids Looming, Hospitals Must Be Prepared

ACIP Considers Single-Dose HPV Vaccination

Suicidal Thoughts in 5% of Adults; CBT's Impact by Disorder; Non-Hallucinogenic LSD?

Surgery for Acute Cholecystitis in Older Adults Tied to Reduced Readmissions

Here's How Psychiatrists Actually Prescribe Medication

CDC Advisors Weigh Switch to Risk-Based COVID Vaccination

WHO Member Nations Agree on Draft 'Pandemic Treaty' to Try to Avoid COVID Mistakes

Can HHS Still Function? Health Data at Risk; Inside Docs' $421M Jury Award

Desktop versie

Tolebrutinib Benefits Non-Relapsing Secondary Progressive Multiple Sclerosis

Medical Industry news